Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420286 | 1.00 | TRPV4 (1.00) | TRPV4CYP11B2CYP11B1EGLN2DAO | |
| SCHEMBL16555923 | 0.82 | TRPV4 (0.69) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL765561 | 0.78 | TRPV4 (0.64) | TRPV4 | |
| SCHEMBL15018039 | 0.77 | TRPV4 (0.62) | TRPV4CYP11B2CYP11B1DAO | |
| SCHEMBL18297999 | 0.76 | CYP11B2 (0.67) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL30919072 | 0.76 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL57346 | 0.76 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL24872449 | 0.76 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1DAO | |
| SCHEMBL1797379 | 0.74 | TRPV4 (0.59) | TRPV4CYP11B2CYP11B1EGLN2 | |
| SCHEMBL9612021 | 0.74 | CYP11B2 (0.68) | TRPV4CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11260049-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| EP-3209732-B1 | SPHINGOSINE-1-PHOSPATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | SCRIPPS RESEARCH INST (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3515888-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| EP-3515888-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2016053855-A1 | SPHINGOSINE-1-PHOSPATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-04-07 | — | — | WO | disclosed |
| US-8816119-B2 | Arylamide derivatives having antiandrogenic properties | MEDEIA THERAPEUTICS LTD (FI) | 2014-08-26 | — | — | US | disclosed |
| WO-2013104829-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | MEDEIA THERAPEUTICS LTD (FI) | 2013-07-18 | — | — | WO | disclosed |
| EP-2593424-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | Medeia Therapeutics Ltd (FI) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109750-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | MEDEIA THERAPEUTICS LTD (FI) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007644-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | MEDEIA THERAPEUTICS LTD (FI) | 2012-01-19 | — | — | WO | disclosed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260049-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP11B2 4042/4885CYP11B1 4316/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | TRPV4 3519/4885CYP11B2 246/4885CYP11B1 273/4885 |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | TRPV4 535/4885CYP11B2 72/4885CYP11B1 87/4885 |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP11B2 4042/4885CYP11B1 4316/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | TRPV4 4878/4885CYP11B2 4416/4885CYP11B1 4434/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | TRPV4 541/4885CYP11B2 113/4885CYP11B1 155/4885 |
| US-20130109750-A1 | NOVEL ARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | AR, NR5A1, CYP19A1 | TRPV4 1823/4885CYP11B2 35/4885CYP11B1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.